Non‑Invasive Diagnosis and Staging of Cirrhosis

Diagnostic Criteria and Elastography Cutoffs

In adults with suspected chronic liver disease, a liver stiffness measurement (LSM) > 12 kPa on transient elastography provides >90 % specificity for compensated advanced chronic liver disease (cACLD) and is considered the primary non‑invasive diagnostic threshold. 1
An LSM > 15 kPa is highly suggestive of cACLD/cirrhosis and can be used to trigger further evaluation for portal‑hypertensive complications. 1
LSM values between 20 kPa and 25 kPa are indicative of clinically significant portal hypertension (CSPH). 1
To rule out cACLD, an LSM < 8 kPa in patients with non‑alcoholic fatty liver disease (NAFLD) or alcoholic liver disease yields >90 % sensitivity. 2
An LSM < 7 kPa in patients with chronic viral hepatitis also provides >90 % sensitivity for excluding cACLD. 1

For chronic hepatitis B infection, a cutoff of 11 kPa balances sensitivity and specificity, accepting more false‑positives because antiviral therapy often lowers stiffness and hepatocellular carcinoma (HCC) surveillance is required regardless of stiffness. 3
In chronic alcoholic liver disease, a threshold of 12.5 kPa achieves 95 % sensitivity and 71 % specificity for detecting cirrhosis. 2
In high‑risk NAFLD populations (older age, obesity, central adiposity, diabetes, markedly elevated ALT), magnetic resonance elastography (MRE) outperforms transient elastography for identifying advanced fibrosis and cirrhosis; estimated cirrhosis prevalence in this group is ≈30 %. 4
In low‑risk NAFLD cohorts (cirrhosis prevalence ≤5 %), current evidence does not support routine elastography screening. 4

Obesity and metabolic syndrome markedly increase false‑positive LSM results when using a generic >10 kPa cutoff; clinicians should interpret stiffness values cautiously in these patients. 1
To improve diagnostic reliability, two LSM assessments performed on separate days are recommended before confirming cACLD. 1
Acute hepatitis, cholestasis, and hepatic congestion can transiently raise LSM values, potentially leading to over‑diagnosis of fibrosis. 1

The AST‑to‑platelet ratio index (APRI) and Fibrosis‑4 (FIB‑4) scores are useful for ruling out advanced fibrosis when values are low, but they lack sufficient accuracy to diagnose CSPH. 1

Abdominal ultrasound is mandatory for all patients; it detects nodular liver surface, coarse echotexture, splenomegaly, and porto‑systemic collaterals—findings that support a diagnosis of cACLD/CSPH. Conventional ultrasound has an AUROC of 0.75–0.80 for compensated cirrhosis. 1
Magnetic resonance elastography (MRE) provides superior diagnostic performance to transient elastography for NAFLD‑related cirrhosis, though its use is limited by cost and availability. [1][4]
CT or MRI should be reviewed for the presence of porto‑systemic collaterals, which are a radiologic hallmark of CSPH and should be routinely reported when identified. 1